삼성바이오에피스

How well do you know the biosimilar landscape?

Biosimilars deliver critical cost savings for healthcare systems in Europe, expanding patient access to biologic treatment options.    Yet many biologics losing exclusivity by 2032 currently have no biosimilars in development. This impacts future supply surety, healthcare resources, and access opportunities.    Discover how supporting long-term biosimilar competition can address this gap on POLITICO Studio: https://lnkd.in/eiwDWYhK     #BiosimilarsInEurope #BiosimilarAccess

We are expanding our commercialization partnership with Organon to four biosimilars in Australia.   The agreement broadens patient access to more affordable treatment options across key therapeutic areas.   🔗 Read the press release: https://lnkd.in/gbuHBQsp

It’s been 10 years since the first immunology biosimilar entered the European market. What does the data collected tell us?   Clinical and real-world evidence show that approved biosimilars match their reference medicines in quality, safety, and efficacy. We have over 1 million patient-treatment years to refer to, with no new safety concerns identified throughout.   Approved biosimilars undergo rigorous regulatory review, meeting high scientific standards that underpin crucial principles including interchangeability and extrapolation.   Explore how biosimilars are backed by a decade of evidence in our second article in a series on Euractiv: https://lnkd.in/gdp6eWRg   #BiosimilarsInEurope #BiosimilarEvidence

Biosimilars and generics are often discussed in similar conversations about access to treatment options.   But while both can help expand access, they are different types of medicines that follow different development and evaluation pathways.   Swipe through our latest “Biosimilars Explained” to learn more.

We're adding years to life. But are we adding life to those years?   Around the world, people are living longer, yet healthy years don't always increase at the same pace.   As healthcare needs continue to evolve, improving access to care and treatment options remains an important part of helping more people live healthier lives. #WorldPopulationDay #InnovatingAccess

Some health journeys last far longer than a hospital visit, a prescription or a treatment plan.   For people with chronic conditions, care often continues through everyday routines, regular monitoring and ongoing support long after the initial diagnosis.   Meeting these long-term needs requires sustainable healthcare systems and access to treatment options, including biosimilars. #ChronicDiseaseDay #chronicdiseaseawareness

Significant policy shifts drove progress across the biosimilar industry during the first half of 2026.   Join us as we review industry milestones alongside company highlights from the last six months in our July issue of Re:Access.   What news has shaped your outlook on the biosimilar industry this year? Share your thoughts in the comments.

We are expanding our partnership with Teva Pharmaceuticals to advance our growth strategy beyond the US and into Canada. This commercialization agreement strengthens our presence in North America, broadening patient access to our ophthalmology biosimilar.   Read the full press release: https://lnkd.in/gaw_C45d

We are collaborating with PROTEINA to develop AI-based antibody therapeutics as part of a Korean government-supported national R&D initiative. By combining our expertise in biosimilar development with Proteina’s high-speed antibody screening technology, we aim to identify multiple AI-designed novel antibody drug candidates by 2027.   🔗 Read the press release: https://lnkd.in/giJfNi3D